HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Oral mucosal decontamination with chlorhexidine for the prevention of ventilator-associated pneumonia in children - a randomized, controlled trial.

AbstractOBJECTIVE:
To study the efficacy of oral mucosal decontamination with chlorhexidine gel for the prevention of ventilator-associated pneumonia in children between 3 months and 15 yrs.
DESIGN:
Double blind randomized placebo controlled trial.
SETTING:
Pediatric intensive care unit of a tertiary care hospital in North India.
PATIENTS:
Eligible participants were patients aged 3 months to 15 yrs who required orotracheal or nasotracheal intubation and mechanical ventilation. Two hundred eighty-three children admitted to the pediatric intensive care unit between November 2007 and April 2009 were screened. Eighty-six patients fulfilled the study requirements.
INTERVENTION:
Either 1% chlorhexidine or placebo gel was applied on the buccal mucosa at 8-hr intervals for the entire duration of ventilation, subject to a maximum of 21 days. Patients were followed up for the development of ventilator-associated pneumonia, diagnosed using the Centers for Disease Control and Prevention criteria.
MAIN OUTCOME MEASURES:
Incidence of ventilator-associated pneumonia, duration of hospital stay, duration of intensive care unit stay, mortality, and characteristics of organisms isolated.
RESULTS:
Fourty-one children received 1% chlorhexidine, whereas 45 received placebo application. Patients of both groups were comparable with respect to baseline characteristics. Incidence of ventilator-associated pneumonia was 39.6/1,000 ventilator days with 1% chlorhexidine and 38.1/1,000 ventilator days with placebo (relative risk 1.03, confidence interval 0.44-2.42, p = .46). The duration of intensive care unit stay and hospital stay was a mean of 8.4 ± 5.8 vs. 9.6 ± 11.4 days (p = .58) and 16.1 ± 10.2 days vs. 15.1 ± 14.3 days (p = .19) with chlorhexidine and placebo, respectively. The mortality rates were similar in the two groups (p = .81). All but two isolates causing ventilator-associated pneumonia were gram-negative, with Acinetobacter species being the most common (14 of 26). No side effects of the applied gel were seen in either group.
CONCLUSION:
Oral mucosal application on 1% chlorhexidine gel did not prevent the development of ventilator-associated pneumonia in children 3 months to 15 yrs age.
AuthorsMeghna Raju Sebastian, Rakesh Lodha, Arti Kapil, Sushil K Kabra
JournalPediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies (Pediatr Crit Care Med) Vol. 13 Issue 5 Pg. e305-10 (Sep 2012) ISSN: 1529-7535 [Print] United States
PMID22760426 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Anti-Infective Agents, Local
  • Chlorhexidine
Topics
  • Acinetobacter
  • Acinetobacter Infections (complications)
  • Administration, Topical
  • Adolescent
  • Anti-Infective Agents, Local (administration & dosage, therapeutic use)
  • Child
  • Child, Preschool
  • Chlorhexidine (administration & dosage, therapeutic use)
  • Decontamination
  • Double-Blind Method
  • Female
  • Humans
  • Infant
  • Intensive Care Units, Pediatric
  • Length of Stay
  • Male
  • Mouth Mucosa (microbiology)
  • Pneumonia, Ventilator-Associated (microbiology, prevention & control)
  • Respiration, Artificial (adverse effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: